Asensus Surgical (ASXC) Stock Price, News & Analysis

Company Overview

Asensus Surgical is a medical technology company specializing in digital laparoscopy and minimally invasive surgical solutions. The company focuses on enhancing surgeon performance and patient outcomes through its proprietary Senhance Surgical System, which integrates advanced instrumentation, software and data analytics. Asensus Surgical’s technology platform is designed to equip operating rooms with digital tools that offer improved visualization, precision and control compared to traditional laparoscopic procedures.

The Senhance Surgical System features haptic feedback, high-definition 3D visualization and eye-tracking camera control to support surgeons during a wide variety of procedures. The system’s ergonomic design and modular architecture enable hospitals and surgical centers to leverage existing operating rooms while benefiting from robotic-style controls. In addition to its core platform, Asensus offers training, technical support and data management services to help healthcare providers optimize surgical workflows and realize consistent clinical results.

Founded in 1999 under a different name, the company originally developed a range of minimally invasive instruments before pivoting to a digital surgery focus. In 2021, the company rebranded as Asensus Surgical to reflect its mission of moving toward knowledge-based surgery through continuous data collection and artificial intelligence–driven insights. Headquartered in Durham, North Carolina, Asensus has established commercial partnerships and distribution channels across North America, Europe, the Middle East and select Asia-Pacific markets.

Under the leadership of President and Chief Executive Officer Anthony Fernando, Asensus Surgical continues to advance its digital surgery portfolio and expand its global footprint. The executive team, supported by an experienced board of directors and clinical advisory panels, remains committed to driving innovation in minimally invasive surgery. By combining robotics-inspired controls with digital intelligence, Asensus aims to empower surgical teams and transform patient care worldwide.

Key Stats

• Today's Range: $0.35 to $0.35
• 50-Day Range: $0.35 to $0.35
• 52-Week Range: $0.17 to $0.40
• Volume: N/A
• Average Volume: 2.03 million shs
• Market Capitalization: $94.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ASXC Stock Analysis - Frequently Asked Questions

How have ASXC shares performed this year?

Asensus Surgical's stock was trading at $0.3479 at the start of the year. Since then, ASXC stock has increased by 0.0% and is now trading at $0.3479.

How were Asensus Surgical's earnings last quarter?

Asensus Surgical, Inc. (NYSEAMERICAN:ASXC) issued its earnings results on Wednesday, November, 3rd. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.01. The company earned $2.57 million during the quarter, compared to analysts' expectations of $1.02 million. Asensus Surgical had a negative trailing twelve-month return on equity of 184.10% and a negative net margin of 902.25%.

How do I buy shares of Asensus Surgical?

Shares of ASXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Asensus Surgical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Asensus Surgical investors own include Digital Turbine (APPS), CrowdStrike (CRWD), ChargePoint (CHPT), SoFi Technologies (SOFI) and Tesla (TSLA).

Company Calendar

• Last Earnings: 11/03/2021
• Today: 7/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSEAMERICAN:ASXC
• CIK: N/A
• Web: www.asensus.com
• Phone: (919) 765-8400
• Fax: 919-765-8459
• Employees: 170
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$78.43 million
• Net Margins: -902.25%
• Pretax Margin: -899.16%
• Return on Equity: -184.10%
• Return on Assets: -114.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.00
• Quick Ratio: 0.69

Sales & Book Value

• Annual Sales: $8.58 million
• Price / Sales: 11.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.13 per share
• Price / Book: 2.68

Miscellaneous

• Outstanding Shares: 272,330,000
• Free Float: 264,516,000
• Market Cap: $94.74 million
• Optionable: Not Optionable
• Beta: 1.37